Table 3 Summary of non-inferiority of live SARS-CoV-2 neutralizing antibody titers between adolescent and young adults who received MVC-COV1901 (in IU/mL).
Per protocol set (PPS) Visit 6 (Day 57) | Adolescents of MVC-COV1901 (N = 334) | Young Adults of MVC-COV1901 (N = 210) | Ratio adolescent/young adults | P-value |
|---|---|---|---|---|
Median (IQR) | 643.62 (980.4) | 444.87 (498.45) | – | – |
Q1–Q3 | 429.67–964.11 | 397.47–916.71 | – | – |
Min–Max | 136.20–3466.39 | 120.46–6976.30 | – | – |
GMT | 648.47 | 559.54 | 1.16 | P < 0.05a |
95% CI | 608.62–690.93 | 512.05–611.34 | 1.04–1.29 |
